Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-04-07

Clinical Trial Update: Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating switching from hydroxyurea to ruxolitinib for relief of polycythemia vera symptoms; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HYDROXYUREA (Hydroxyurea)
  • Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Polycythemia Vera | Phase 3 | Status: COMPLETED | Results posted: 2015-04-07